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Lymph node metastases associated with prostate cancer (PCa) has been shown to be a poor prognostic factor. The role of pelvic
lymph node dissection (PLND) itself in relation to survival remains unclear, however. A Medline search was conducted to address
this issue. The following conclusions were drawn. Only recently, improved survival due to completion of radical prostatectomy
(RP) (compared to abandoning RP) in known or presumed lymph-node-positive patients has been shown. Lymph node sampling
can only be considered representative if an adequate number of nodes is removed. While several authors have suggested that a
therapeutic benefit in patients undergoing RP is not provided by PLND, the reliability of these studies is uncertain. Contrary to
this, several studies have indicated the possibility of long-term survival even in the presence of limited lymph node metastases. The
role and timing of initiation of adjuvant androgen deprivation therapy (ADT) in patients who have node-positive disease after RP
is controversial. Recent studies suggest that delaying ADT may not adversely impact survival.
1. Introduction
Lymph node metastases in men diagnosed with PCa has
been shown to be a poor prognostic factor for biochemical
recurrence (BCR) and survival [1–3]. As part of the stage
migration in PCa during the PSA era, the incidence of
positive lymph nodes has decreased steadily [1, 4]. Nev-
ertheless, accurate identification and staging of men with
lymph node metastases allows more precise prognostication
and may have important implications on the initiation
of adjuvant therapy [5]. Surgical excision and histological
examination of the pelvic lymph nodes provides the most
accurate staging information regarding pelvic lymph node
status [6–8]. The role of PLND in relation to survival
remains, however, unclear. Furthermore, switching from a
limited nodal dissection to an extended one (ePNLD) is
associated with a 14.6% complications rate which in most
papers is higher than that of a more limited dissection [8]. Of
course, the benefit of performing an ePLND must outweigh
the elevated risk of complications.
We sought to review the available literature concerning
the role of PLND and RP on survival outcome.
2. Evidence Acquisition
A Medline search was conducted to identify original articles
addressing the role of PLND in PCa. Keywords included
prostate cancer, pelvic lymph node dissection, and radical
prostatectomy. All of the keywords are within the Medical
Subject Headings (MeSH) database. Original articles with
the highest level of evidence were identified and were
critically reviewed.s
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3. Evidence Synthesis
3.1. Localization of Nodes Draining the Prostate. The lym-
phatic drainage of the prostate gland has been described
more than 100 years ago [9]. Three regions are con-
cerned: common iliac, external iliac, and hypogastric. These
anatomic findings have been confirmed clinically through
extended nodal dissections revealing positive nodes outside
the obturator fossa, namely, around the common iliac artery
and the hypogastric pedicle in 22% and 29%, respectively
[10]. Therefore, all these sites have to be considered while
performing an extended pelvic lymph node dissection.
3.2. Number of Nodes Removed. Since the number of positive
lymph nodes detected is strongly correlated to the number
of nodes removed, lymph node sampling can only be con-
sidered representative if an adequate number of nodes and
all relevantly located nodes are removed [4–8, 11–16]. An
autopsy study by Weinga¨rtner et al. suggests that 20 lymph
nodes must be removed for an adequate PLND [17]. Several
studies have shown this requirement to be technically feasible
by harvesting a comparable number of lymph nodes in vivo
[2, 7, 8, 13, 18, 19]. Reports on patients who underwent
more limited PLND might be misleading and incomplete
lymph node sampling probably will not provide an accurate
prognostic factor for survival. A certain percentage of cases
would be considered lymph node negative (pN0) because
metastases were not detected merely by the limited extent of
PLND performed. Such patients would be left with residual
tumor and perhaps deprived of the chance of cure.
However, maybe being even more important than the
absolute number of nodes, the anatomical boundaries of
PLND should be considered since there is a natural vari-
ability in the number of nodes encountered in one patient
compared to another. Moreover, as is the case in radical
cystectomy, the differences in methods by which lymphatic
tissues are collected, transported, and processed by the
pathologist could lead to a significant difference in nodal
count. Thus, the absolute number of nodes counted might
be misleading [20].
Irrespective of the nodal status, an increased absolute
number of nodes removed have been suggested to be
associated with better cancer control for some tumors, such
as colon or bladder cancer [21]. In PCa, this has been tested
in only one retrospective cohort, without any benefit for
relapse [14]. But major limitations must be highlighted, such
as the median number of removed nodes (only 9), and a
statistical analysis performed on only 174 patients with pos-
itive nodes. Using the SEER database, a positive relationship
was observed between the total number of nodes removed,
and PCa-specific survival. Surprisingly, the difference was
observed in PLND with >4 nodes, which is far below the
expected number of an ePLND [13, 16]. Confirmatory
analysis based on prospective data is mandatory.
3.3. Indications for PLND. Indications for PLND are subject
to debate. The guidelines of the European Association of
Urology indicate that a PLND should be undertaken in men
with intermediate (cT2a, PSA 10–20 ng/mL, biopsy Gleason
score 7) or high-risk (>cT2b, PSA >20 ng/mL, Gleason score
≥8) PCa, when the nomogram-estimated risk for positive
nodes exceeds 7% [22]. Meanwhile, there are other authors
who recommend performing ePLND in all patients with a
PSA level of≥10 ng/mL, and in all patients with a PSA level of
<10 ng/mL with a Gleason score >6 [4]. The definition of the
indication for PLND lies not within the scope of this paper,
nor is the incorporation of sentinel node sampling within the
diagnostic armamentarium.
3.4. pN0 Patients. Several authors have suggested that a
therapeutic benefit in patients undergoing RP is not provided
by PLND. DiMarco et al. reported that the extent of
lymphadenectomy does not affect cancer outcome in lymph
node negative cases thereby making the impact of PLND
negligible in the overall population, or in patients stratified
as having high-risk PCa based on the D’Amico classification
(1059 high risk patients) [23]. This single institution analysis
on a cohort of 7036 patients undergoing RP with or without
PLND over a 13 yr time span has several limitations. Since
conclusions were drawn from a pN0 PCa population of
which 71% of patients had Gleason score ≤6, 95% had
organ confined disease and only 26% had a PSA >10 ng/mL,
no definite conclusions can be drawn for the entire PCa
population, especially for patients with high risk PCa or
lymph node invasion (pN1). Moreover, the mean number of
nodes removed per patient in this study was only 9. Bearing
in mind the strong correlation between the total number of
nodes removed and the number of positive nodes detected,
underestimation of lymph node invasion is inherent to more
limited PLND rendering any conclusion on survival based
on a less than extended PLND doubtful. Finally, therapeutic
outcome in terms of BCR was the same between the patients
operated at the beginning of the author’s experience with
a more extensive PLND compared to those operated 10 yr
later with a minimal PLND despite a significant shift in
tumor stage. It cannot be excluded that more extensive
PLND in their early experience might have had an influence
on recurrence and survival because one would expect a
poorer outcome for the earlier group, considering the higher
frequency of locally advanced PCA in this era.
Murphy et al. showed in a similar population of 964
pN0 patients with low median PSA of 6.2 ng/mL, of which
only 36.5% of patients had Gleason score ≥7 and 99.5%
had clinically organ confined disease, that the number of
nodes removed was not significantly associated with BCR
[24], thereby questioning the role of PLND. Again this
type of population does not warrant conclusions for PCa
patients at higher risk of disseminated disease. Moreover, the
anatomical extent of the PLND performed was not captured
in this study. The internal iliac region is often omitted when
performing PNLD, although lymph nodemetastasis is said to
be found in this region in 62% of cases [13]. The absence of
knowledge on the regional extent of PLND might introduce
an inherent bias.
Bhatta-Dhar et al. also failed to find a statistically sig-
nificant difference in the 6-year BCR-free survival rate in a
low-risk PCa population who did or did not undergo PLND
[25]. Conclusions for the entire population of PCa patients
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(with intermediate and high-risk patients included) cannot
be drawn, especially not for those with pN1 PCa. Moreover,
a followup of 6 years is too short when considering the typical
protracted natural history of PCa.
In summary, the reliability of studies showing that PLND
does not confer a survival benefit in pN0 is uncertain.
A last comment regards the definition of pN0 patients.
Are the analyzed nodes really negative? In a retrospective
single centre analysis of 4,611 patients, Masterson et al.
showed a positive impact on BCR-free survival resulting
from an increased total number of nodes removed in pN0
patients [14]. It was speculated that this might have been
due to cellular disease that had escaped identification, but
was treated effectively with ePLND. This may indeed be
considered since using modified pathological analysis such
as systematic immunohistochemistry analysis [26] or RT-
PCR [27] increases the node positivity by 13.3% and 26.6%,
respectively. Interestingly, patients with an upstaged nodal
status using those techniques showed the same cancer-related
outcomes compared to those who were initially staged pN1.
3.5. pN1 Patients. Although no prospective randomized
clinical trials are available, several studies have indicated
the possibility of long-term survival even in the presence of
limited lymph node metastases [3, 5, 6, 16, 18].
Based on a population of 367 patients who underwent
RP and extended PLND, Bader et al. concluded that some
patients with minimal metastatic disease in the lymph nodes
remain free of BCR for more than 10 years after surgery
without adjuvant treatment [18]. This finding implies a
possible therapeutic effect of PLND, especially since in this
report any adjuvant treatment was deferred until symptoms
of disease progression occurred.
Likewise, Allaf et al. showed that a significant benefit in
BCR-free survival may exist for certain subgroups of pN1
PCa patients undergoing RP with extended PLND [5]. In this
single centre study including 4,000 patients, the outcomes of
RP with limited PLND (all performed by surgeon A) were
compared to those of RP with extended PLND (performed
by surgeon B). There was a trend towards improved BCR-
free survival in patients who underwent extended dissection.
In a subset of patients with nodal involvement and less than
15% positive lymph nodes, there was a statistically significant
difference between PLND techniques with respect to BCR.
However, given the low number of patients with positive
lymph nodes, this study could be underpowered.
The same group retrospectively analyzed a population
of 3,264 patients undergoing RP with extended PLND [28].
Nodal involvement was present in 143 patients (4.4%),
and these patients only underwent adjuvant treatment after
clinical disease recurrence occurred. In the multivariate
analysis, 15% or greater positive lymph nodes was a signif-
icant predictor of BCR. Stratifying patients simultaneously
according to the 3 strongest prognostic factors made it
possible to define a subset of pN1 patients that showed 5-
year BCR-free survival of 52% (i.e., for patients with <15%
positive lymph nodes and Gleason score ≤7 and absence of
seminal vesicle invasion). An important limitation of this
study was that BCR was defined as end-point, rather than
clinical progression or survival.
The concept and prognostic significance of the percent-
age of positive lymph nodes or lymph node density was
further elaborated in a single centre retrospective analysis of
235 pN1 patients after RP with extended PLND [2]. 69%
of these patients did not undergo any adjuvant treatment.
Lymph node density was defined as the number of positive
nodes divided by the total number of nodes removed. When
stratified by lymph node density, patients with a density of
20% or greater were at higher risk for clinical recurrence
compared to those with a density of less than 20% (RR:
2.31; P < 0.001). In patients with lymph node density less
than 20% the mean 10-year clinical recurrence-free survival
rate was 72% compared to 47% in those with a lymph node
density 20% or greater.
Probability of long-term survival after RP with or with-
out subsequent androgen deprivation therapy, even with
the presence of limited lymph node metastases, was also
observed in a study of 13,020 patients undergoing RP
obtained from the Surveillance, Epidemiology, and End
Result Program (SEER) [16]. Patients undergoing excision
of at least 4 lymph nodes (node-positive and node-negative
patients) or more than 10 nodes (only node-negative
patients) had a lower risk of prostate cancer-specific death
at 10 years than did those who did not undergo PLND. This
is only possible if a percentage of patients with macroscopic
as well as microscopic lymph node invasion is cured by
more extensive PLND. Using the SEER database poses several
evident limitations: lack of information regarding adjuvant
hormonal treatment, lack of information on other patient
characteristics, inability to control formargin status, and lack
of PSA data for some of the patients included.
A large retrospective analysis from the Mayo Clinic
confirmed the finding that RP may offer long-term survival
to patients with pN1 PCa [11]. In 507 patients identified
as pN1 at RP with extended PLND, cancer-specific survival
(CSS) depended amongst other variables on the degree of
lymph node involvement. Ten-year CSS was as high as 86%.
While in this last study 90% of patients received adjuvant
ADT, Schumacher et al. reported on 122 pN1 patients after
RP who did not receive any ADT. They confirmed good
long-term BCR-free survival and CSS for patients with low-
volume nodal burden after RP [6]. For patients with 1
positive lymph node, 10-year BCR-free survival and CSS
were 24.7% and 72.1%, respectively. In patients with 2
positive lymph nodes, 10-year BCR-free survival and CSS
were still 11.8% and 79.1%, respectively.
The exact definition of “low-volume nodal burden” por-
tending good survival was further elaborated by Fleischmann
et al. in a single-centre study of 102 node-positive patients
who did not receive adjuvant ADT [15]. On multivariate
analysis, the diameter of the largest metastasis was the
strongest prognostic factor for all end points (BCR, CSS, and
overall survival). On the other hand, Briganti et al. emphasize
on the absolute number of nodes affected when they state
that ≥2 positive nodes represent a significant cutoff value
for predicting CSS in patients with node-positive PCa after
RP [7, 8]. Important limitations of this study were the fact
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that all patients were submitted to adjuvant ADT, differences
in population characteristics between the two contributing
institutions as well as differences in the way the lymph nodes
were sent for pathological examination.
3.6. cN1 Patients. Until recently, there was only limited data
to support completing RP in known or presumed lymph-
node-positive patients. Using a population-based database,
Engel and Bastian showed that patients with pN1 disease
at frozen section analysis may experience improved survival
when RP is completed, compared to patients with abandoned
RP [29]. This obvious advantage should encourage urologists
to complete RP, regardless of lymph node status, and
therefore omit frozen section analysis of lymph nodes. Their
conclusions were based on 13,805 patients with histologically
confirmed PCa included in the Munich Cancer Registry.
Differences in survival were impressive, and in favor of
patients with completed RP, even in node-positive cases. Of
course, a formal prospective trial would be the only way to
get a definitive answer on this issue, but this is unlikely to
ever be done.
3.7. Adjuvant Treatments. Although ADT has a well-defined
role in patients who have metastatic disease and in patients
who are undergoing radiotherapy for high-risk disease,
its role in patients who have node-positive disease after
RP is controversial. Messing et al. reported the results of
a randomized, controlled clinical trial in men with pN1
after RP, comparing life-long immediate adjuvant ADT with
ADT at the time of metastatic disease. The study reported
a significant advantage in progression-free survival and
overall survival that favored early adjuvant ADT [30]. Given
the potential for long-term adverse effects associated with
ADT, such as osteoporosis, cardiovascular disease, diabetes,
and mood disorders, delaying the initiation of ADT until
documented BCR may spare patients significant treatment-
related toxicities. In a large cohort of 731 pN1 patients
after RP, Wong et al. compared administration of adjuvant
ADT with patients who did not receive adjuvant ADT. The
results suggest that the delay of ADT may not adversely
impact CSS, nor overall survival [31]. This cohort of patients
was constructed using linked SEER—Medicare data implying
several limitations as already has been mentioned before. In
a similar setting, Schro¨der et al. reported on the result of
EORTC 30846, which examined the role of immediate versus
delayed ADT in patients who had node-positive disease
and who did not undergo RP. There was no difference in
overall survival between the early and deferred ADT arms
[32]. The most likely reason for these conflicting results
is the difference in indication for initiation of ADT in
the groups that were initially observed. In the study by
Messing et al., patients were only started on ADT if they
developed clinical metastases, which is associated with a high
risk of both CSS and overall mortality. However, in more
recent trials, post-RP monitoring of PSA became routine
and patients in these series likely were followed for BCR.
Hypothetically, treatment with ADT at the time of BCR may
be successful in the treatment of micrometastatic disease and
in the prevention of the onset of metastatic disease (and
possibly subsequent death from PCa). This hypothesis may
be a possible explanation for the improved outcomes in
the delayed treatment arm of the above-mentioned series
[31, 32]. Further studies support such hypothesis. D’Amico
et al. proved a PSA doubling time of less than 3 months is
a surrogate end point of CSS. Therefore, these men are most
likely to benefit most from the extended, relatively symptom-
free interval provided by early salvage ADT [33]. Whether
or not adding ADT at the time of BCR actually improves
survival remains to be clarified. In the literature, only few
retrospective papers show evidence of some improvement
in CSS and even in overall survival [34, 35]. Anyhow, the
promising survival rate of patients with very low-volume
nodal burden after surgery alone (RP and PLND) makes
the value of routine immediate ADT in all patients with
lymph node metastases at least questionable, especially when
considering the negative side effects [18].
Another interesting aspect of adjuvant therapy was
alluded to by da Pozzo et al. [19]. This group was the first to
investigate the role of ADT with or without radiation therapy
in node-positive patients. All 250 patients underwent RP
with extended PLND andwere submitted to adjuvant ADT in
this single centre report. They found a significant protective
role for adjuvant ADT together with radiation therapy
in CSS. Important limitations of this study are the two
different radiation therapy regimens that were used (26%
underwent irradiation of the prostatic bed only, while 74%
also underwent pelvis irradiation) and data regarding quality
of life related to the delivery of adjuvant radiation therapy
were not obtained. Therefore, it can so far only be considered
as hypothesis generating and cannot be considered standard
of care.
4. Conclusions
From this Medline search concerning the role of PLND and
RP on survival outcome, the following conclusions were
drawn. First, lymph node sampling can only be considered
representative if an adequate number of nodes and all
relevantly located nodes are removed. Second, while several
authors have suggested that a therapeutic benefit in patients
undergoing RP is not provided by PLND, the reliability
of these studies is uncertain. Third, several studies have
indicated the possibility of long-term survival even in the
presence of very limited lymph node metastases provided
patients had an extended PLND. Fourth, improved survival
after completion of RP (compared to abandoning RP)
in known or presumed lymph-node-positive patients has
recently been shown. Fifth, although ADT has a well-defined
role in patients who have metastatic disease or in patients
with high-risk localized disease undergoing radiotherapy,
its role in patients who have node-positive disease after
RP is controversial. Historically, a significant advantage in
progression-free survival and overall survival was attributed
to immediate adjuvant ADT after RP. However, this evi-
dence was acquired in a pre-PSA, small-sized prospective
randomized trial in which most patients had high-volume
nodal tumor burden. The translation of those results
towards contemporary pN1 patients—who frequently have
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low-volume nodal tumor burden in an extended PLND—is
problematic.
Authors’ Contribution
Anthony Van Baelen and Nicolas Mottet contributed equally
to the paper.
References
[1] M. Han, A. W. Partin, S. Piantadosi, J. I. Epstein, and P. C.
Walsh, “Era specific biochemical recurrence-free survival fol-
lowing radical prostatectomy for clinically localized prostate
cancer,” The Journal of Urology, vol. 166, no. 2, pp. 416–419,
2001.
[2] S. Daneshmand, M. L. Quek, J. P. Stein et al., “Prognosis of
patients with lymph node positive prostate cancer following
radical prostatectomy: long-term results,” The Journal of
Urology, vol. 172, no. 6, 1, pp. 2252–2255, 2004.
[3] L. Cheng, H. Zincke, M. L. Blute, E. J. Bergstralh, B. Scherer,
and D. G. Bostwick, “Risk of prostate carcinoma death in
patients with lymph node metastasis,” Cancer, vol. 91, no. 1,
pp. 66–73, 2001.
[4] P. Bader, F. C. Burkhard, R. Markwalder, and U. E. Studer, “Is a
limited lymph node dissection an adequate staging procedure
for prostate cancer?” The Journal of Urology, vol. 168, no. 2, pp.
514–518, 2002.
[5] M. E. Allaf, G. S. Palapattu, B. J. Trock, H. B. Carter, and P. C.
Walsh, “Anatomical extent of lymph node dissection: impact
on men with clinically localized prostate cancer,” The Journal
of Urology, vol. 172, no. 5, 1, pp. 1840–1844, 2004.
[6] M. C. Schumacher, F. C. Burkhard, G. N. Thalmann, A.
Fleischmann, and U. E. Studer, “Good outcome for patients
with few lymph node metastases after radical retropubic
prostatectomy,” European Urology, vol. 54, no. 2, pp. 344–352,
2008.
[7] A. Briganti, J. R. Karnes, L. F. da Pozzo et al., “Two positive
nodes represent a significant cut-off value for cancer specific
survival in patients with node positive prostate cancer. A
new proposal based on a two-institution experience on 703
consecutive N+ patients treated with radical prostatectomy,
extended pelvic lymph node dissection and adjuvant therapy,”
European Urology, vol. 55, no. 2, pp. 261–270, 2009.
[8] A. Briganti, M. L. Blute, J. H. Eastham et al., “Pelvic lymph
node dissection in prostate cancer,” European Urology, vol. 55,
no. 6, pp. 1251–1265, 2009.
[9] B. Cune´o and M. Marcille, “Topographie des ganglions ilio-
pelviens,” Bulletin et Memoires de la Societe d’Anthropologie de
Paris, vol. 3, pp. 653–663, 1901.
[10] F. C. Burkhard and U. E. Studer, “The role of lymphadenec-
tomy in high risk prostate cancer,” The World Journal of
Urology, vol. 26, no. 3, pp. 231–236, 2008.
[11] S. A. Boorjian, R. H. Thompson, S. Siddiqui et al., “Long-term
outcome after radical prostatectomy for patients with lymph
node positive prostate cancer in the prostate specific antigen
era,” The Journal of Urology, vol. 178, no. 3, 1, pp. 864–871,
2007.
[12] C. Lindberg, T. Davidsson, S. Gudjo´nsson, R. Hilmarsson, F.
Liedberg, and O. Bratt, “Extended pelvic lymphadenectomy
for prostate cancer: will the previously reported benefits be
reproduced in hospitals with lower surgical volumes?” The
Scandinavian Journal of Urology and Nephrology, vol. 43, no.
6, pp. 437–441, 2009.
[13] A. Heidenreich, Z. Varga, and R. von Knobloch, “Extended
pelvic lymphadenectomy in patients undergoing radical
prostatectomy: high incidence of lymph node metastasis,” The
Journal of Urology, vol. 167, no. 4, pp. 1681–1686, 2002.
[14] T. A. Masterson, F. J. Bianco, A. J. Vickers et al., “The
association between total and positive lymph node counts, and
disease progression in clinically localized prostate cancer,” The
Journal of Urology, vol. 175, no. 4, pp. 1320–1324, 2006.
[15] A. Fleischmann, S. Schobinger, M. Schumacher, G. N. Thal-
mann, and U. E. Studer, “Survival in surgically treated, nodal
positive prostate cancer patients is predicted by histopatholog-
ical characteristics of the primary tumor and its lymph node
metastases,” The Prostate, vol. 69, no. 4, pp. 352–362, 2009.
[16] S. A. Joslyn and B. R. Konety, “Impact of extent of lym-
phadenectomy on survival after radical prostatectomy for
prostate cancer,” Urology, vol. 68, no. 1, pp. 121–125, 2006.
[17] K. Weinga¨rtner, A. Ramaswamy, A. Bittinger, E. W. Gerharz,
D. Vo¨ge, and H. Riedmiller, “Anatomical basis for pelvic
lymphadenectomy in prostate cancer: results of an autopsy
study and implications for the clinic,” The Journal of Urology,
vol. 156, no. 6, pp. 1969–1971, 1996.
[18] P. Bader, F. C. Burkhard, R. Markwalder, and U. E. Studer,
“Disease progression and survival of patients with positive
lymph nodes after radical prostatectomy. Is there a chance of
cure?” The Journal of Urology, vol. 169, no. 3, pp. 849–854,
2003.
[19] L. F. da Pozzo, C. Cozzarini, A. Briganti et al., “Long-
term follow-up of patients with prostate cancer and nodal
metastases treated by pelvic lymphadenectomy and radical
prostatectomy: the positive impact of adjuvant radiotherapy,”
European Urology, vol. 55, no. 5, pp. 1003–1011, 2009.
[20] J. P. Stein, D. F. Penson, J. Cai et al., “Radical cystectomy
with extended lymphadenectomy: evaluating separate package
versus en bloc submission for node positive bladder cancer,”
The Journal of Urology, vol. 177, no. 3, pp. 876–882, 2007.
[21] Koppie Cancer 2006.
[22] A. Heidenreich, G. Aus, M. Bolla et al., “EAU guidelines on
prostate cancer. European association of urology,” European
Urology, vol. 53, no. 1, pp. 68–80, 2008.
[23] D. S. DiMarco, H. Zincke, T. J. Sebo, J. Slezak, E. J. Bergstralh,
andM. L. Blute, “The extent of lymphadenectomy for pTXNO
prostate cancer does not affect prostate cancer outcome in the
prostate specific antigen era,” The Journal of Urology, vol. 173,
no. 4, pp. 1121–1125, 2005.
[24] A. M. Murphy, D. S. Berkman, M. Desai, M. C. Benson, J. M.
McKiernan, and K. K. Badani, “The number of negative pelvic
lymph nodes removed does not affect the risk of biochemical
failure after radical prostatectomy,” The British Journal of
Urology International, vol. 105, no. 2, pp. 176–179, 2010.
[25] N. Bhatta-Dhar, A. M. Reuther, C. Zippe, and E. A. Klein, “No
difference in six-year biochemical failure rates with or without
pelvic lymph node dissection during radical prostatectomy in
low-risk patients with localized prostate cancer,” Urology, vol.
63, no. 3, pp. 528–531, 2004.
[26] V. Pagliarulo, D. Hawes, F. H. Brands et al., “Detection of
occult lymph node metastases in locally advanced node-
negative prostate cancer,” The Journal of Clinical Oncology, vol.
24, no. 18, pp. 2735–2742, 2006.
[27] T. Terakawa, H. Miyake, T. Kurahashi, J. Furukawa, A. Tak-
enaka, and M. Fujisawa, “Improved sensitivity for detecting
micrometastases in pelvic lymph nodes by real-time reverse
transcriptase polymerase chain reaction (RT-PCR) compared
with conventional RT-PCR in patients with clinically localized
prostate cancer undergoing radical prostatectomy,” The British
6 Advances in Urology
Journal of Urology International, vol. 103, no. 8, pp. 1074–1078,
2009.
[28] G. S. Palapattu, M. E. Allaf, B. J. Trock, J. I. Epstein, and
P. C. Walsh, “Prostate specific antigen progression in men
with lymph node metastases following radical prostatectomy:
results of long-term followup,”The Journal of Urology, vol. 172,
no. 5, 1, pp. 1860–1864, 2004.
[29] J. Engel, P. J. Bastian, H. Baur et al., “Survival benefit of radical
prostatectomy in lymph node-positive patients with prostate
cancer,” European Urology, vol. 57, no. 5, pp. 754–761, 2010.
[30] E. M. Messing, J. Manola, J. Yao et al., “Immediate versus
deferred androgen deprivation treatment in patients with
node-positive prostate cancer after radical prostatectomy and
pelvic lymphadenectomy,” The Lancet Oncology, vol. 7, no. 6,
pp. 472–479, 2006.
[31] Y. N.Wong, S. Freedland, B. Egleston, G. Hitdes, J. S. Schwartz,
and K. Armstrong, “Role of androgen deprivation therapy
for node-positive prostate cancer,” The Journal of Clinical
Oncology, vol. 27, no. 1, pp. 100–105, 2009.
[32] F. H. Schro¨der, K. H. Kurth, S. D. Fossa et al., “Early versus
delayed endocrine treatment of T2-T3 pN1-3 M0 prostate
cancer without local treatment of the primary tumour:
final results of European organisation for the research and
treatment of cancer protocol 30846 after 13 years of follow-
up (a randomised controlled trial),” European Urology, vol. 55,
no. 1, pp. 14–22, 2009.
[33] A. V. d’Amico, J. Moul, P. R. Carroll et al., “Prostate specific
antigen doubling time as a surrogate end point for prostate
cancer specific mortality following radical prostatectomy or
radiation therapy,” The Journal of Urology, vol. 172, no. 5, 2,
pp. S42–S47, 2004.
[34] S. A. Siddiqui, S. A. Boorjian, B. Inman, S. Bagniewski, E. J.
Bergstralh, and M. L. Blute, “Timing of androgen deprivation
therapy and its impact on survival after radical prostatectomy:
a matched cohort study,” The Journal of Urology, vol. 179, no.
5, pp. 1830–1837, 2008.
[35] T. K. Choueiri, M. H. Chen, A. V. d’Amico et al., “Impact of
postoperative prostate-specific antigen disease recurrence and
the use of salvage therapy on the risk of death,” Cancer, vol.
116, no. 8, pp. 1887–1892, 2010.
Submit your manuscripts at
http://www.hindawi.com
Stem Cells
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
MEDIATORS
INFLAMMATION
of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Behavioural 
Neurology
Endocrinology
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Disease Markers
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
BioMed 
Research International
Oncology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Oxidative Medicine and 
Cellular Longevity
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
PPAR Research
The Scientific 
World Journal
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Immunology Research
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Journal of
Obesity
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
 Computational and  
Mathematical Methods 
in Medicine
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Research and Treatment
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Parkinson’s 
Disease
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com
